Corma-Gomez, AnaïsFernandez-Fuertes, MartaGarcia, EstefaniaFuentes-Lopez, AnaGomez-Ayerbe, CristinaRivero-Juarez, AntonioDominguez, CarmenSantos, MartaViñuela, LauraPalacios, RosarioReal, Luis MRivero, AntonioMacias, JuanPineda, Juan AGarcia, Federico2023-05-032023-05-032022-05-14Corma-Gómez A, Fernández-Fuertes M, García E, Fuentes-López A, Gómez-Ayerbe C, Rivero-Juárez A, et al. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV. Clin Microbiol Infect. 2022 Nov;28(11):1492-1498http://hdl.handle.net/10668/22132The aim of this study was to assess the immunogenicity of SARS-CoV-2 available vaccines among people living with HIV (PLWH) after a complete vaccination scheme, and determine predictors of seroconversion. This multicentre prospective cohort study included 420 PLWH who had received a standard immunization, either with mRNA or adenoviral-vectored COVID-19 vaccines. Antibody response was evaluated within 1 to 2 months after the last dose of the vaccine with a quantitative determination of antitrimeric spike protein-specific IgG antibodies and IgG neutralizing antibodies. Overall, 384 of 420 PLWH (91%) showed antibody response to vaccination. Seroconversion was observed in 308 of 326 individuals with cluster of differentiation 4 (CD4) counts ≥350 cells/mm3 (95%), 55 of 61 PLWH with 200 to 349 cells/mm3 (90%), and 21 of 33 PLWH with CD4 counts HIV-related immunosuppression impairs the antibody response to SARS-CoV-2 vaccines. Specific vaccination schemes should be urgently tailored in this setting, particularly in patients with CD4 cell countsenCD4 T-cell countsHumoral responsePeople living with HIVSARS-CoV-2VaccineÁrea de Gestión Sanitaria Sur de SevillaHumansCOVID-19 VaccinesSpike Glycoprotein, CoronavirusSARS-CoV-2Prospective StudiesAntibodies, ViralCOVID-19Antibodies, NeutralizingImmunoglobulin GImmunosuppression TherapyVaccinationImmunologic Deficiency SyndromesHIV InfectionsRNA, Messengerresearch article35640840open accessARN mensajeroAnticuerpos antiviralesAnticuerpos neutralizantesGlicoproteína de la espiga del coronavirusInfecciones por VIHInmunoglobulina GSíndromes de inmunodeficiencia10.1016/j.cmi.2022.05.0181469-0691PMC9144847https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144847https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144847/pdf